August 2016

Leapcure, Scientist.com partner to accelerate patient recruitment

Wednesday, August 31, 2016

Leapcure, a provider of patient engagement solutions for clinical trials and pharmaceutical research, has teamed up with Scientist.com, a marketplace for pharmaceutical services, to provide patient recruitment services for users of Scientist.com’s network of 10 pharmaceutical research marketplaces. The partnership will provide white-label, global clinical recruitment services using Leapcure’s smart patient engagement platform.

[Read More]

Medivir proceeds with a separation of the company’s operations

Wednesday, August 31, 2016

Medivir has announced that the Board of Directors has tasked the company management to continue the implementation of a separation of the company’s operations into two independent companies, with the intention to obtain a separate listing on First North Premium for the new commercial company based on Medivir’s current pharmaceutical portfolio. The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio.

[Read More]

Vention Medical adds new facility in Ireland

Wednesday, August 31, 2016

Vention Medical has opened an additional facility in Ireland to more closely collaborate with customers in the region and accelerate their development initiatives. The new facility will provide medical device design and development services and house Vention’s team of dedicated development professionals.

[Read More]

DCRI, Pfizer, Premier partner on vaccination rates

Tuesday, August 30, 2016

A new quality improvement initiative that aims to create effective solutions in optimizing adult vaccination rates has been announced. The program, the Adult Immunization Project, is a collaboration among the Duke Clinical Research Institute (DCRI), Duke Primary Care, Pfizer and Premier. Researchers will jointly work to develop evidence-based interventions to support indicated adult vaccination practices among providers in the Duke Health system.

[Read More]

Forbes names Incyte to list of World’s Most Innovative Companies

Tuesday, August 30, 2016

Incyte has been ranked 4th on Forbes magazine’s 2016 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.

[Read More]

Biothera Pharmaceuticals, Merck expand cancer immunotherapy collaboration

Tuesday, August 30, 2016

Biothera Pharmaceuticals has announced a collaboration with Merck, known as MSD outside the U.S. and Canada, to expand the companies’ ongoing clinical program evaluating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 inhibitor, in combination with Biothera’s Imprime PGG, a Pathogen Associated Molecular Patterning molecule, or PAMP. Imprime PGG acts as an immunological “ignition switch” enlisting the innate immune system to enhance the therapeutic efficacy of tumor targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies.

[Read More]